Successful use of continuous subcutaneous Foslevodopa/Foscarbidopa in Parkinson's disease with bipolar disorder without psychiatric destabilization
Joanna Siuda, Justyna Gawryluk, Amelia Krupczak, Mateusz Toś · 2026
Read Successful use of continuous subcutaneous Foslevodopa/Foscarbidopa in Parkinson's disease with bipolar disorder without psychiatric destabilization by Joanna Siuda, Justyna Gawryluk, Amelia Krupczak, Mateusz Toś (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13324501.txt.
Description
Joanna Siuda and colleagues describe a hard treatment balance in a 2026 case report on Parkinson disease with bipolar disorder. Drugs that lift dopamine can unsettle mood, while mood drugs can worsen movement, which narrows choices for both illnesses.
Their patient, a 47-year-old man with bipolar disorder since age 18, developed Parkinson signs at 36 and later strong motor swings. Several mood drugs had failed or caused harm before lurasidone, quetiapine, and lamotrigine steadied him. A steady skin infusion of foslevodopa and foscarbidopa then eased his motor fluctuations. Mood stayed stable through treatment, with no psychiatric breakdown. The case hints this infusion may suit some patients once barred from advanced dopamine therapy.
Catalog record
| CREATOR | Joanna Siuda, Justyna Gawryluk, Amelia Krupczak, Mateusz Toś |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8965 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |